FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Gould Robert J					2. Issuer Name and Ticker or Trading Symbol Fulcrum Therapeutics, Inc. [ FULC ]							(Che	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner			
(Last) (First) (Middle) C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET					3. Date of Earliest Transaction (Month/Day/Year) 02/02/2021					2	X Officer (give title Other (specify below)  See Remarks					
(Street) CAMBRIDGE MA 02139  (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)  vative Securities Acquired, Disposed of, or Benefic						Line	5. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				
1. Title of Security (Instr. 3)		Transacti ate			3. Transac Code (Ir 8)	tion	4. Securi	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		5. Amount of Securities Beneficially		orm: Direct ) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Table II - De					uired, Di , options					Owned			
1. Title of Derivative Security (Instr. 3)	Conversion Date or Exercise (Month/Day/Year) i		3A. Deemed Execution Date if any (Month/Day/Yea	Code	ransaction ode (Instr. Acqu or Di of (D		Derivative Ex		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
_				Code	v	(A)		Date Exercisable		epiration ate	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (right to buy)	\$11.33	02/02/2021		A		269,390		(1)	02	2/01/2031	Common Stock	269,390	\$0.00	269,390	D	

## **Explanation of Responses:**

1. This option was granted on February 2, 2021 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2021, subject to continued service.

## Remarks:

President & Chief Executive Officer

/s/ Peter Thomson, as attorney-02/04/2021 in-fact for Robert J. Gould

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.